Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 1,000 | $129.00 | $129,000.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,093 Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 1,000 | $38.40 | $38,400.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 5,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,226 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 9,500 | $127.50 | $1,211,250.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 5,000 | $38.40 | $192,000.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC |
LANE ANDREW HEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 135,925 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · derivative · entry 4 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 135,925 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC |
LANE ANDREW HEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 135,925 | $125.48 | $17,055,189.38 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,087 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.96 to $125.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC |
LANE ANDREW HEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 135,925 | $38.40 | $5,219,520.00 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 10,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,726 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 14,500 | $125.00 | $1,812,500.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 10,000 | $38.40 | $384,000.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 8,000 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,978 Underlying: Common Shares · 8,000 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC |
Karam SammySENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 8,000 | $125.00 | $1,000,000.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 8,000 | $75.90 | $607,200.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 13, 2021 21:15 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003917 · form4-08132021_020829.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103,945 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 8,000 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,978 Underlying: Common Shares · 8,000 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC |
Karam SammySENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 8,000 | $122.50 | $980,000.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 8,000 | $75.90 | $607,200.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:40 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 1,245 | $120.98 | $150,620.10 |
DisclosureSEC source: 0001415889-21-003773 · form4-08032021_020823.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,345 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 17,600 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · derivative · entry 3 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,600 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 17,600 | $120.33 | $2,117,881.92 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,691 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.3203 to $120.35, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 17,600 | $50.72 | $892,672.00 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:09 UTC |
Calamari Christopher J.SENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 19,291 | $0.00 Strike: $116.40 | $0.00 |
DisclosureSEC source: 0001415889-21-003509 · form4-07062021_020756.xml · derivative · entry 4 Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,291 Underlying: Common Shares · 19,291 shares Expires 2031-06-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,430 on July 1, 2022, 6,430 on July 1, 2023 and 6,431 on July 1, 2024. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:09 UTC |
Calamari Christopher J.SENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 3,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003509 · form4-07062021_020756.xml · nonDerivative · entry 1 Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,920 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:22 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 19,291 | $0.00 Strike: $116.40 | $0.00 |
DisclosureSEC source: 0001415889-21-003513 · form4-07062021_020716.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,291 Underlying: Common Shares · 19,291 shares Expires 2031-06-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,430 on July 1, 2022, 6,430 on July 1, 2023, and 6,431 on July 1, 2024. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:22 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 3,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003513 · form4-07062021_020716.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:32 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 35,995 | $0.00 Strike: $116.40 | $0.00 |
DisclosureSEC source: 0001415889-21-003516 · form4-07062021_020708.xml · derivative · entry 3 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,995 Underlying: Common Shares · 35,995 shares Expires 2031-06-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,998 on July 1, 2022, 11,998 on July 1, 2023 and 11,999 on July 1, 2024. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:32 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 5,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003516 · form4-07062021_020708.xml · nonDerivative · entry 1 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,772 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:01 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 67 | $115.93 | $7,767.31 |
DisclosureSEC source: 0001415889-21-003418 · form4-07022021_020756.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,408 Underlying: Common Shares · 67 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:05 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 189 | $115.93 | $21,910.77 |
DisclosureSEC source: 0001415889-21-003423 · form4-07022021_020728.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189 Underlying: Common Shares · 189 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:06 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 284 | $115.93 | $32,924.12 |
DisclosureSEC source: 0001415889-21-003425 · form4-07022021_020723.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,654 Underlying: Common Shares · 284 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 25, 2021 Filed Jul 2, 2021 21:08 UTC |
Ford Robert BDirector · PRESIDENT AND CEO
|
GiftCommon shares without par value | 28,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003428 · form4-07022021_020723.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 163,989 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| June 25, 2021 Filed Jul 2, 2021 21:08 UTC |
Ford Robert BDirector · PRESIDENT AND CEO
|
GiftCommon shares without par value | 28,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003428 · form4-07022021_020723.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,072 Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 21:09 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 2,881 | $109.05 | $314,173.05 |
DisclosureSEC source: 0001415889-21-002958 · form4-06112021_020627.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,494 Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:31 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 1,768 | $106.90 | $188,999.20 |
DisclosureSEC source: 0001415889-21-002830 · form4-06072021_020640.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,553 Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:33 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 1,768 | $106.90 | $188,999.20 |
DisclosureSEC source: 0001415889-21-002831 · form4-06072021_020648.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy · Derivative | 68,000 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · derivative · entry 7 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,987 Underlying: Common Shares · 68,000 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 17,043 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · derivative · entry 6 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,043 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 85,043 | $119.89 | $10,195,626.68 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,783 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.38 to $120.13, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 68,000 | $59.94 | $4,075,920.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 17,043 | $44.40 | $756,709.20 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 9,533 | $120.02 | $1,144,112.53 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,783 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.0103 to $120.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:38 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GiftCommon shares without par value | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002225 · form4-04302021_020445.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,650 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:38 UTC |
BIRD ROGERSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 9,439 | $122.00 | $1,151,558.00 |
DisclosureSEC source: 0001415889-21-002194 · form4-04292021_030450.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,083 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:42 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 8,600 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-002195 · form4-04292021_030442.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,978 Underlying: Common Shares · 8,600 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:42 UTC |
Karam SammySENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 8,600 | $122.00 | $1,049,200.00 |
DisclosureSEC source: 0001415889-21-002195 · form4-04292021_030442.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.